HER2-directed TKIs (like zongertinib) and ADCs (trastuzumab-deruxtecan/TDXD) have different mechanisms, and clinical data shows they are effective when used sequentially. Zongertinib works post-TDXD, and vice-versa. However, there is no evidence to support using one HER2 TKI after another has failed.

Unlike broader-spectrum tyrosine kinase inhibitors, zungertinib is highly selective for HER2 and avoids targeting wild-type EGFR. This specific mechanism is crucial as it leads to a better toxicity profile, particularly reducing the common EGFR-related side effects of rash and diarrhea, improving patient tolerability.

The specific type of HER2 mutation significantly impacts TKI efficacy. YVMA exon 20 insertions show the highest response rates. Other TKD (tyrosine kinase domain) mutations perform moderately well, while non-TKD mutations respond poorly. This molecular nuance is critical for predicting treatment success and managing patient expectations.

Despite both Zongertinib and Sevabirtinib showing high efficacy in HER2-mutant NSCLC, Zongertinib's selective nature results in a much better safety profile. Sevabirtinib's dual EGFR/HER2 inhibition leads to significant GI and skin toxicities, making tolerability, not just efficacy, the key factor for clinical preference.

An expert oncologist indicated a willingness to use the TKI zongertinib off-label for stage III HER2-mutant NSCLC patients after chemoradiation, instead of the standard-of-care immunotherapy (durvalumab). This reflects a strong conviction that for driver mutation-positive cancers, targeted therapy is superior, even ahead of definitive clinical trial data in this specific setting.

For HER2-mutant NSCLC, Zongertinib (a TKI) is now the first-line choice. While TKIs show activity after ADCs like TDXD, the effectiveness of using an ADC after TKI failure remains an unproven but critical clinical question for oncologists.

The new treatment paradigm for HER2-positive lung cancer will likely involve sequencing a TKI like zongertinib first, followed by an antibody-drug conjugate (ADC). Early data suggests that the efficacy of TKIs is significantly reduced when used after an ADC, making the TKI-first approach critical for maximizing patient outcomes.

The recent first-line FDA approval of the oral TKI zungertinib fundamentally alters the treatment paradigm for HER2-mutant non-small cell lung cancer. This shifts the standard of care away from initial platinum-based chemotherapy, forcing oncologists to reconsider the sequencing of TKIs, antibody-drug conjugates, and chemotherapy.

Zongertinib specifically targets HER2 while sparing EGFR, resulting in minimal GI and skin toxicities. In contrast, Sevabertinib inhibits both HER2 and EGFR, causing significantly higher rates of diarrhea. This makes Zongertinib a better-tolerated option for patients requiring a HER2-directed TKI.